Posts tagged clinical studies
Titan Pharma treats first patient with PD implant

Titan Pharmaceuticals (NASDAQ:TTNP) has treated the first patient in a Phase 1/2 trial of its ropinirole implant intended for the treatment of signs and symptoms of idiopathic Parkinson's disease (PD).

Read More
IntelGenx closes second tranche of convertible debenture financing

IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) closed a second tranche of its prospectus offering of convertible debentures, raising additional proceeds of CDN $762,000.

Read More
Tetra in cannabis pact with Constance Therapeutics

Tetra Bio-Pharma (OTCQB:TBPMF; CSE:TBP) has signed a letter of intent with Constance Therapeutics of San Francisco for the clinical development and commercialization in Canada of its signature medicinal cannabis extract products.

Read More
IntelGenx completes sale of convertible debentures

IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) closed a previously announced prospectus offering of convertible unsecured subordinated debentures for gross proceeds of more than $6.8-million.

Read More
IntelGenx files final prospectus for debenture offering

IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) has filed a final short form prospectus in connection with its previously announced offering of a minimum of $5-million and a maximum of $10-million principal amount of 8% convertible unsecured subordinated debentures due June 30, 2020.

Read More
GeneNews launches risk stratification test for breast cancer

GeneNews (TSX:GEN) has launched BreastSentry, a new risk stratification test for breast cancer, via its Virginia-based clinical reference lab, Innovative Diagnostics Laboratory (IDL).

Read More
HCW downgrades Agenus to neutral

H.C. Wainwright downgraded Agenus (NASDAQ:AGEN) to “neutral” from “buy” and slashed its price target to $5 from $10. The stock closed at $4.33 on Thursday.

Analyst Swayampakula Ramakanth writes that during Agenus’ third quarter earnings, the company announced development of CTLA-4 and PD-1 checkpoint modulators (CPMs) as the focus of the company’s cancer immunotherapy pipeline.

Read More